Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Copegus Ribavirin 200mg Film coated tablet Roche Products (NZ) Limited Patheon Inc, Ontario, Canada
|
Product: Active Ingredient:
Dosage Form: New Zealand Sponsor: Manufacturer:
|
Metvix Methyl aminolevulinate hydrochloride 200mg/g equivalent to Methyl aminolevulinate 160mg/g Topical cream Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics Penn Pharmaceutical Services Limited, Gwent, United Kingdom
|
Product:
Active Ingredient: Dosage Form: Manufacturers:
Active Ingredient: Dosage Form: Manufacturers:
New Zealand Sponsor:
|
Pegasys RBV (Combination Product) Component 1 Peginterferon alfa-2a 270mcg/mL Solution for injection F Hoffmann-La Roche Limited, Basel, Switzerland F Hoffmann-La Roche Limited, Kaiseraugst, Switzerland Roche Diagnostics GmbH, Mannheim, Germany Component 2 Ribavirin 200mg Film coated tablet Hoffmann-La Roche Inc, New Jersey, United States of America Patheon Inc, Ontario, Canada Roche Products (NZ) Limited
|
Product:
Active Ingredient: Dosage Form: Manufacturers:
Active Ingredient: Dosage Form: Manufacturers:
New Zealand Sponsor:
|
Pegasys RBV (Combination Product) Component 1 Peginterferon alfa-2a 360mcg/mL Solution for injection F Hoffmann-La Roche Limited, Basel, Switzerland F Hoffmann-La Roche Limited, Kaiseraugst, Switzerland Roche Diagnostics GmbH, Mannheim, Germany Component 2 Ribavirin 200mg Film coated tablet Hoffmann-La Roche Inc, New Jersey, United States of America Patheon Inc, Ontario, Canada Roche Products (NZ) Limited
|
Dated this 8th day of May 2015.
CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).